# Mirum Pharmaceuticals Stock Rises as LIVMARLI Meets All Endpoints in Phase 3 Trial

- URL: https://stocks.freetheai.org/news/mirum-pharmaceuticals-stock-rises-as-livmarli-meets-all-endpoints-in-phase-3-363ca0
- Published: 2026-10-12T12:00:00Z
- Category: company_news; sentiment: bullish; impact: high
- Symbols: [NASDAQ:MIRM](https://stocks.freetheai.org/symbols/NASDAQ-MIRM)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Mirum Pharmaceuticals, Inc. (MIRM) announced that its Phase 3 EXPAND study evaluating LIVMARLI successfully met its primary itch endpoint alongside all five secondary endpoints. Patients treated with the drug experienced a statistically significant reduction in itch severity compared to placebo. Additionally, serum bile acids decreased by 70.1% in the treatment group versus 3.5% for placebo, with no new safety signals reported. Shares of the company gained 5.73% to trade at $86.01 following the updates.

The study demonstrates clinical progress in expanding LIVMARLI beyond its established indications for Alagille syndrome and progressive familial intrahepatic cholestasis. Achieving positive trial results in broader cholestatic liver conditions, including biliary atresia, lowers development risk and opens access to an underserved patient population.

Looking ahead, Mirum Pharmaceuticals plans to submit a U.S. supplemental New Drug Application in the first half of 2027. Investors will be tracking key future catalysts, including regulatory submission acceptance, label scope decisions, and potential commercial expansion into international markets.

## Key points

- LIVMARLI met its primary itch endpoint in the Phase 3 EXPAND study with a statistically significant p-value of 0.0004.
- All five secondary trial endpoints were met, including a 70.1% reduction in serum bile acids compared to 3.5% for placebo.
- The trial revealed no new safety signals while evaluating ultra-rare conditions such as biliary atresia.
- Mirum Pharmaceuticals plans to submit a U.S. supplemental New Drug Application in the first half of 2027.
- Mirum Pharmaceuticals stock increased 5.73% to $86.01 following the trial results.

## Questions and answers

### What were the results of the Phase 3 trial for LIVMARLI?

The Phase 3 EXPAND study met its primary itch endpoint and all five secondary endpoints, showing a 70.1% reduction in serum bile acids with no new safety concerns.

### When will Mirum Pharmaceuticals seek U.S. approval for LIVMARLI?

Mirum Pharmaceuticals plans to file a supplemental New Drug Application with U.S. regulators in the first half of 2027.

### How did Mirum Pharmaceuticals stock react to the trial news?

Mirum Pharmaceuticals stock increased by 5.73% to reach $86.01 after the clinical results were released.